Orphazyme's fate sealed as creditors approve Kempharm sale

On Monday, the biotech firm’s creditors have adopted a proposed restructuring plan, clearing the way forward to selling Orphazyme’s activities to US-based Kempharm.

Photo: Orphazyme/PR

Creditors of Orphazyme, a publicly listed biotech firm in Denmark, have accepted the restructuring plans that would see the firm sold off to US-based Kempharm, the Danish company has announced in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs